Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
Aims: To examine medication adherence and discontinuation in two separate groups of
patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting …
patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting …
Paliperidone palmitate: a breakthrough treatment for schizophrenia? A review on patient adherence levels, healthcare resource utilization and costs
S Bramante, G Di Salvo, G Maina… - … Disease and Treatment, 2023 - Taylor & Francis
International guidelines suggest long-term antipsychotic therapies for treating
schizophrenia; however, medication compliance remains a critical issue in schizophrenia …
schizophrenia; however, medication compliance remains a critical issue in schizophrenia …
Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: a systematic review and meta-analysis of cohort …
S Lee, S Schwartz - Psychiatry research, 2021 - Elsevier
The purpose of this systematic review and meta-analysis was to assess adherence and
persistence to long-acting injectable dopamine receptor blocking agents (LAI DRBAs) in …
persistence to long-acting injectable dopamine receptor blocking agents (LAI DRBAs) in …
Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I …
Introduction Few studies have compared adherence between long-acting injectable
antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM …
antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM …
Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real …
Objective: Early initiation of antipsychotic treatment in schizophrenia is associated with
improved outcomes. This study aimed to determine if initiation of long-acting injectable (LAI) …
improved outcomes. This study aimed to determine if initiation of long-acting injectable (LAI) …
Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting
K Joshi, MH Lafeuille, B Brown, W Wynant… - … medical research and …, 2017 - Taylor & Francis
Abstract Objectives: Since May 2015, adult patients with schizophrenia adequately treated
with once monthly paliperidone palmitate (PP1M) may be transitioned to once-every-three …
with once monthly paliperidone palmitate (PP1M) may be transitioned to once-every-three …
Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals
C Xu, SA Ferrante, T Fitzgerald, CD Pericone… - Journal of Managed Care …, 2023 - jmcp.org
BACKGROUND: Days supply values reported in large administrative claims databases are
commonly used to estimate drug exposure and quantify adherence and persistence with …
commonly used to estimate drug exposure and quantify adherence and persistence with …
Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
Introduction In general, racial and ethnic differences exist in antipsychotic prescription
practices. However, little is known about such differences between individual long-acting …
practices. However, little is known about such differences between individual long-acting …
Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective …
Objective: To compare rehospitalizations in patients with schizophrenia treated with
paliperidone palmitate (PP1M) vs oral atypical antipsychotics (OAAs), with a focus on young …
paliperidone palmitate (PP1M) vs oral atypical antipsychotics (OAAs), with a focus on young …
Adherence of patients with schizophrenia to hypothyroidism treatment
S Gur, S Weizman, H Hermesh, A Matalon… - … Prisms: Global Mental …, 2023 - cambridge.org
Adherence to prescription medications is critical for both remission from schizophrenia and
control of physical comorbidities. While schizophrenia with comorbid hypothyroidism is …
control of physical comorbidities. While schizophrenia with comorbid hypothyroidism is …